Endokanabinoid Sistem, İnsülin Direnci ve Yağ Asitleri Arasındaki İlişki

Endokanabinoid sistem, enerji dengesinin sağlanmasında kritik bir rol oynayan hücrelerarası sinyal sistemidir. Bu nedenle, başta obezite olmak üzere insülin direnci, diyabet ve yeme bozuklukları gibi enerji dengesinin bozulmasıyla karakterize hastalıkların tedavisine yönelik yeni bir araştırma konusu haline gelmiştir. Endokanabinoid sistemin aktive olması beyinde etkili olup iştahı arttıran uyarılara neden olmaktadır. Bununla birlikte, lipogenezi arttırarak, adiponektin üretimini ve periferik dokularda glukoz kullanımını azaltarak insülin direncine yol açmaktadır. Yapılan araştırmalar, endokanabinoidlerin besin alımının düzenlenmesinde rolü olduğu gibi beslenme tarzının veya beslenme örüntüsünün de endokanabinoid düzeyi üzerinde etkileri olduğunu göstermektedir. Ancak, endokanabinoid sistem üzerinde etkisi kesin olarak kanıtlanabilmiş spesifik besin ögesinin olup olmadığına ilişkin veriler veya kanabinoidlerin insülin direnci üzerinde potansiyel terapötik geçerliği üzerine yapılan çalışmalar henüz yetersizdir.

Relationship Between Endocannabinoid System, Insulin Resistance and Fatty Acids

The endocannabinoid system is an intracellular signaling system playing a critical role in ensuring the energy balance. Thus it has become a new research topic for treatment diseases, including mainly obesity, insulin resistance, diabetes and eating disorders, characterized by impairment of energy balance. The activation of the endocannabinoid system causes signals increasing appetite by effective in brain. Moreover, by increasing lipogenesis and decreasing adiponectin production and glucose utilization in peripheral tissues, it causes insulin resistance. Researches showed that dietary profile or nutritional pattern are effective on endocannabinoid level as endocannabinoids are effective on regulation of food intake. However, data related whether or not there is a specific nutrient effecting endocannabinoid system or studies related to cannabinoids that have therapeutic effect on insulin resistance are insufficient.

___

  • 1. Carr TP, Jesch ED, Brown AW. Endocannabinoids, metabolic regulation, and the role of diet. Nutr Res 2008;28:641-650.
  • 2. Scheen AJ. The endocannabinoid system: a promising target for the management of type 2 diabetes. Curr Protein Pept Sci 2009;10:56-74.
  • 3. Davis SN, Perkins JM. Role of the endocannabinoid system in management of patients with type 2 diabetes mellitus and cardiovascular risk factors. Endocr Pract 2007;13:790-804.
  • 4. Ashton CH. Pharmacology and effects of cannabis: a brief review. Br J Psychiatry 2001;178:101-106.
  • 5. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990;346:561-564.
  • 6. Horvath B, Mukhopadhyay P, Hasko G, Pacher P. The endocannabinoid system and plant-derived cannabinoids in diabetes and diabetic complications. Am J Pathol 2012;180:432-442.
  • 7. Grotenhermen F. Clinical pharmacodynamics of cannabinoids. Journal of Cannabis Therapeutics 2004;4:29- 78.
  • 8. Jorge P. The endocannabinoid system and the regulation of energy metabolism. Diabetes care. Supplement 2006:1-23.
  • 9. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006;55:3053-3060.
  • 10. Lu D, Dopart R, Kendall DA. Controlled downregulation of the cannabinoid CB1 receptor provides a promising approach for the treatment of obesity and obesity-derived type 2 diabetes. Cell Stress Chaperones 2016;21(1):1-7.
  • 11. Iranmanesh A, Rosenstock J, Hollander P. SERENADE: rimonabant monotherapy for treatment of multiple cardiometabolic risk factors in treatment-naive patients with type 2 diabetes. Diabet Med 2006;23:230.
  • 12. Matias I, Di Marzo V. Endocannabinoids and the control of energy balance. Trends Endocrinol Metab 2007;18:27-37.
  • 13. Hansen HS, Moesgaard B, Hansen HH, Petersen G. N-Acylethanolamines and precursor phospholipids - relation to cell injury. Chem Phys Lipids 2000;108:135- 150.
  • 14. Naughton SS, Mathai ML, Hryciw DH, McAinch AJ. Fatty Acid modulation of the endocannabinoid system and the effect on food intake and metabolism. Int J Endocrinol 2013; 361895.
  • 15. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 1996;384:83-87.
  • 16. Spoto B, Fezza F, Parlongo G, Battista N, Sgro E, Gasperi V, et al. Human adipose tissue binds and metabolizes the endocannabinoids anandamide and 2-arachidonoylglycerol. Biochimie 2006;88:1889-1897.
  • 17. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006;91:3171-3180.
  • 18. Ravinet Trillou C, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, et al. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003;284:R345-353.
  • 19. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003;112:423-431.
  • 20. Despres JP, Golay A, Sjostrom L, Rimonabant in Obesity-Lipids Study G. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005;353:2121-2134.
  • 21. Scheen AJ, Finer N, Hollander P, Jensen MD, Van Gaal LF, Group RI-DS. Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006;368:1660-1672.
  • 22. Roche R, Hoareau L, Bes-Houtmann S, Gonthier MP, Laborde C, Baron JF, et al. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem Cell Biol 2006;126:177- 187.
  • 23. Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proc Natl Acad Sci USA 2003;100:1393-1398.
  • 24. Taylor R. Insulin resistance and type 2 diabetes. Diabetes 2012;61:778-779.
  • 25. Vettor R, Pagano C. The role of the endocannabinoid system in lipogenesis and fatty acid metabolism. Best Pract Res Clin Endocrinol Metab 2009;23:51-63.
  • 26. Di Marzo V, Goparaju SK, Wang L, Liu J, Batkai S, Jarai Z, et al. Leptin-regulated endocannabinoids are involved in maintaining food intake. Nature 2001;410:822- 825.
  • 27. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 2001;86:1930-1935.
  • 28. Jeffrey Kim YL, Bruce A. Watkins. Endocannabinoid signaling and energy metabolism: A target for dietaryintervention. Nutrition 2011;27:624-632.
  • 29. Osei-Hyiaman D, DePetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005;115:1298-1305.
  • 30. Tam J, Liu J, Mukhopadhyay B, Cinar R, Godlewski G, Kunos G. Endocannabinoids in liver disease. Hepatology 2011;53:346-355.
  • 31. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, et al. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008;16:553-565.
  • 32. Matias I, Petrosino S, Racioppi A, Capasso R, Izzo AA, Di Marzo V. Dysregulation of peripheral endocannabinoid levels in hyperglycemia and obesity: Effect of high fat diets. Mol Cell Endocrinol 2008;286:S66-78.
  • 33. Willson TM, Lambert MH, Kliewer SA. Peroxisome proliferator-activated receptor gamma and metabolic disease. Annu Rev Biochem 2001;70:341-367.
  • 34. Nakata M, Yada T. Cannabinoids inhibit insulin secretion and cytosolic Ca2+ oscillation in islet beta-cells via CB1 receptors. Regul Pept 2008;145:49-53.
  • 35. Bermudez-Silva FJ, Suarez J, Baixeras E, Cobo N, Bautista D, Cuesta-Munoz AL, et al. Presence of functional cannabinoid receptors in human endocrine pancreas. Diabetologia 2008;51:476-487.
  • 36. Kirkham TC, Williams CM, Fezza F, Di Marzo V. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002;136:550-557.
  • 37. Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, et al. Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 2015;36:277-296.
  • 38. Liu YL, Connoley IP, Wilson CA, Stock MJ. Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005;29:183-187.
  • 39. Cavuoto P, McAinch AJ, Hatzinikolas G, CameronSmith D, Wittert GA. Effects of cannabinoid receptors on skeletal muscle oxidative pathways. Mol Cell Endocrinol 2007;267:63-69.
  • 40. Kutluay-Merdol T, Alphan E, Hıncal F. Endokannabinoid sistem kardiyovasküler risk faktörleri yönetiminde yeni bir tedavi hedefi olabilir mi? Türk Kardiyoloji Seminerleri 2008;8(2):169-178.
  • 41. Nogueiras R, Rohner-Jeanrenaud F, Woods SC, Tschop MH. The endocannabinoid system and the control of glucose homeostasis. J Neuroendocrinol 2008;20 Suppl 1:147-151.
  • 42. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, et al. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007;31:692- 699.
  • 43. Cleland SJ, Sattar N. Does rimonabant pull its weight for type 2 diabetes? Lancet 2006;368:1632-1634.
  • 44. Nissen SE, Nicholls SJ, Wolski K, Rodes-Cabau J, Cannon CP, Deanfield JE, et al. Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. JAMA 2008;299:1547-1560.
  • 45. Monteleone AM, Dimarzo V, Monteleone P, Dalle Grave R, Aveta T, Ghoch ME, et.al. Responses of peripheral endocannabinoids and endocannabinoid-related compounds to hedonic eating in obesity. Eur J Nutr 2016;55:1799-1805.
  • 46. Liu J, Zhou L, Xiong K, Godlewski G, Mukhopadhyay B, Tam J, et al. Hepatic cannabinoid receptor-1 mediates diet-induced insulin resistance via inhibition of insulin signaling and clearance in mice. Gastroenterology 2012;142:1218-1228 e1211.
  • 47. Hanus L, Avraham Y, Ben-Shushan D, Zolotarev O, Berry EM, Mechoulam R. Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res 2003;983:144-151.
  • 48. Jeong WI, Osei-Hyiaman D, Park O, Liu J, Batkai S, Mukhopadhyay P, et al. Paracrine activation of hepatic CB1 receptors by stellate cell-derived endocannabinoids mediates alcoholic fatty liver. Cell Metab 2008;7:227-235.
  • 49. Tsuyama S, Oikawa D, Yamasaki Y, Takagi S, Ando H, Furuse M. Expression of endocannabinoid synthetic enzyme mRnas is correlated with cannabinoid 1 receptor mRNA in the mouse brain. Nutr Neurosci 2007;10:45-50.
  • 50. Wood JT, Williams JS, Pandarinathan L, Janero DR, Lammi-Keefe CJ, Makriyannis A. Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res 2010;51:1416-1423.
  • 51. Batetta B, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, et al. Endocannabinoids may mediate the ability of (n-3) fatty acids to reduce ectopic fat and inflammatory mediators in obese Zucker rats. J Nutr 2009;139:1495-1501.
  • 52. Di Marzo V, Griinari M, Carta G, Murru E, Ligresti A, Cordeddu L, et al. Dietary krill oil increases docosahexaenoic acid and reduces 2-arachidonoylglycerol but not N-acylethanolamine levels in the brain of obese Zucker rats. Int Dairy J 2010;20:231-235.